AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	509	78-44-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: carisoprodol carisoprodate isomeprobamate isopropyl meprobamate	A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202) Molecular weight: 260.33 Formula: C12H24N2O4 CLOGP: 2.34 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 90.65 ALOGS: -2.52 ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

carisoprodol
carisoprodate
isomeprobamate
isopropyl meprobamate

A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)

Molecular weight: 260.33
Formula: C12H24N2O4
CLOGP: 2.34
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 90.65
ALOGS: -2.52
ROTB: 9

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.40	g	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	76.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.203		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.614		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	54.325	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	6.383	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	53.050	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	64.320	%	High	1
herg	hERG pIC50	4.400	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	3.062	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	18.880	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	51.670	%	High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	3.524		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	28.576		High	1
mppb	Mouse plasma protein binding (% unbound)	50.120		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	9.183		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	66.610	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	27.669	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	90.810	%	High	1
rppb	Rat plasma protein binding (% unbound)	44.040	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	891.251	uM	High	1

Approvals:

Date	Agency	Company	Orphan
April 9, 1959	FDA	MEDA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	1667.82	14.26	793	22907	144265	90460482
Respiratory arrest	712.39	14.26	283	23417	33028	90571719
Toxicity to various agents	582.13	14.26	529	23171	287317	90317430
Cardiac arrest	441.74	14.26	298	23402	104637	90500110
Cardio-respiratory arrest	303.63	14.26	195	23505	62945	90541802
Drug abuse	274.67	14.26	203	23497	82144	90522603
Poisoning	167.18	14.26	81	23619	15136	90589611
Overdose	149.68	14.26	195	23505	157514	90447233
Drug abuser	122.36	14.26	40	23660	2650	90602097
Drug dependence	117.72	14.26	81	23619	29246	90575501
Drug withdrawal syndrome	116.87	14.26	80	23620	28643	90576104
Intentional product misuse	111.30	14.26	127	23573	89477	90515270
Accidental overdose	108.58	14.26	76	23624	28197	90576550
Off label use	104.07	14.26	82	23618	1102170	89502577
Unresponsive to stimuli	96.68	14.26	80	23620	38041	90566706
Exposure via ingestion	91.15	14.26	32	23668	2635	90602112
Coma	83.58	14.26	99	23601	72533	90532214
Maternal exposure during pregnancy	81.00	14.26	3	23697	360060	90244687
Dependence	78.80	14.26	27	23673	2068	90602679
Infusion related reaction	75.31	14.26	10	23690	416770	90187977
Contraindicated product administered	70.87	14.26	3	23697	320136	90284611
Depression	68.53	14.26	203	23497	300398	90304349
Systemic lupus erythematosus	60.11	14.26	11	23689	361885	90242862
Urinary bladder rupture	58.70	14.26	13	23687	188	90604559
Wound	57.86	14.26	6	23694	302974	90301773
Narcotic bowel syndrome	56.96	14.26	12	23688	135	90604612
Drug screen positive	56.91	14.26	25	23675	3732	90601015
Anxiety	56.70	14.26	194	23506	309578	90295169
Drug intolerance	55.20	14.26	24	23676	447567	90157180
Lethargy	55.09	14.26	75	23625	63064	90541683
Accidental death	52.95	14.26	20	23680	2028	90602719
Intentional overdose	52.90	14.26	91	23609	93743	90511004
Discomfort	48.54	14.26	7	23693	274328	90330419
Seizure	46.73	14.26	115	23585	152514	90452233
Product use in unapproved indication	46.51	14.26	15	23685	336221	90268526
Joint swelling	45.36	14.26	39	23661	503261	90101486
Hepatic enzyme increased	45.01	14.26	19	23681	360717	90244030
Feeling abnormal	42.97	14.26	118	23582	167117	90437630
Lower respiratory tract infection	40.79	14.26	8	23692	250651	90354096
Emotional distress	40.56	14.26	49	23651	36613	90568134
Alopecia	40.35	14.26	42	23658	495029	90109718
Helicobacter infection	39.64	14.26	6	23694	226844	90377903
Abdominal discomfort	37.22	14.26	42	23658	477286	90127461
Intervertebral disc protrusion	36.22	14.26	40	23660	27156	90577591
Rash	35.11	14.26	100	23600	796000	89808747
Loss of consciousness	35.08	14.26	98	23602	140140	90464607
Stomatitis	35.01	14.26	14	23686	274684	90330063
Soft tissue haemorrhage	34.25	14.26	9	23691	275	90604472
Somnolence	33.97	14.26	126	23574	208958	90395789
Liver injury	33.54	14.26	3	23697	170564	90434183
Muscle injury	32.45	14.26	4	23696	176650	90428097
Death	32.25	14.26	217	23483	456334	90148413
Insomnia	32.19	14.26	172	23528	333302	90271445
Product use issue	31.65	14.26	24	23676	329895	90274852
Purpura senile	31.46	14.26	10	23690	605	90604142
Impaired healing	31.41	14.26	11	23689	234188	90370559
Blister	30.89	14.26	14	23686	254984	90349763
Back pain	30.88	14.26	164	23536	317011	90287736
Spinal epidural haematoma	30.81	14.26	12	23688	1322	90603425
Suspected suicide	30.53	14.26	23	23677	9545	90595202
Infection	30.30	14.26	30	23670	362064	90242683
Pulmonary congestion	30.15	14.26	31	23669	19402	90585345
Arthropathy	29.90	14.26	31	23669	366211	90238536
Ill-defined disorder	29.87	14.26	6	23694	184885	90419862
Suicidal ideation	29.66	14.26	62	23638	73793	90530954
Peripheral swelling	28.39	14.26	40	23660	413066	90191681
Tarsal tunnel syndrome	27.95	14.26	9	23691	568	90604179
Quadriplegia	27.94	14.26	13	23687	2218	90602529
Neutropenia	27.79	14.26	12	23688	224892	90379855
C-reactive protein increased	27.08	14.26	7	23693	181382	90423365
Coronary artery disease	26.43	14.26	38	23662	33585	90571162
Crying	26.31	14.26	33	23667	25612	90579135
Intervertebral disc degeneration	25.80	14.26	27	23673	17247	90587500
Mobility decreased	25.67	14.26	17	23683	250717	90354030
General physical health deterioration	24.78	14.26	34	23666	355081	90249666
Exposure during pregnancy	24.63	14.26	16	23684	238394	90366353
Tremor	24.61	14.26	92	23608	153081	90451666
Psoriatic arthropathy	24.03	14.26	15	23685	228320	90376427
Hyperhidrosis	23.70	14.26	84	23616	136221	90468526
Fall	23.43	14.26	210	23490	481600	90123147
Inadequate analgesia	23.41	14.26	13	23687	3211	90601536
Mydriasis	23.39	14.26	24	23676	14988	90589759
Type 2 diabetes mellitus	23.33	14.26	12	23688	203232	90401515
Blood pH decreased	23.32	14.26	12	23688	2546	90602201
Suicide attempt	23.26	14.26	57	23643	75342	90529405
Distributive shock	22.68	14.26	13	23687	3411	90601336
Respiratory depression	22.65	14.26	24	23676	15551	90589196
Hypersensitivity	22.37	14.26	54	23646	454623	90150124
Febrile neutropenia	21.99	14.26	7	23693	158342	90446405
Wheezing	21.96	14.26	18	23682	238062	90366685
Product complaint	21.79	14.26	22	23678	13478	90591269
Thrombocytopenia	21.57	14.26	14	23686	208711	90396036
Resorption bone increased	21.39	14.26	9	23691	1210	90603537
Pleural adhesion	21.34	14.26	5	23695	94	90604653
Nasopharyngitis	21.11	14.26	47	23653	407057	90197690
Mental status changes	20.93	14.26	40	23660	44639	90560108
Drowning	20.74	14.26	7	23693	512	90604235
Irritability	20.63	14.26	35	23665	35627	90569120
Thinking abnormal	20.57	14.26	20	23680	11712	90593035
Nervousness	20.47	14.26	34	23666	34022	90570725
Impaired driving ability	20.07	14.26	14	23686	5159	90599588
Arteriosclerosis	19.97	14.26	19	23681	10834	90593913
Hyperlipidaemia	19.65	14.26	27	23673	22889	90581858
Drug ineffective	19.35	14.26	251	23449	1384047	89220700
Vestibular disorder	19.32	14.26	9	23691	1540	90603207
Musculoskeletal stiffness	19.10	14.26	30	23670	296502	90308245
Therapeutic product effect incomplete	18.72	14.26	14	23686	193882	90410865
Stress	18.52	14.26	55	23645	81340	90523407
Withdrawal syndrome	18.50	14.26	26	23674	22498	90582249
Inflammation	18.42	14.26	12	23688	178580	90426167
Progressive multiple sclerosis	17.64	14.26	8	23692	1286	90603461
Abnormal dreams	17.54	14.26	18	23682	11239	90593508
Migraine	17.53	14.26	97	23603	190295	90414452
Pain	17.48	14.26	361	23339	995980	89608767
Gastrointestinal disorder	17.47	14.26	25	23675	256662	90348085
Pancytopenia	17.27	14.26	5	23695	120258	90484489
Substance abuse	17.26	14.26	13	23687	5393	90599354
Pneumonia aspiration	17.18	14.26	35	23665	40905	90563842
Therapeutic product effect decreased	17.02	14.26	29	23671	277542	90327205
Bronchitis	16.91	14.26	82	23618	152845	90451902
Pre-existing condition improved	16.77	14.26	16	23684	9153	90595594
Multiple sclerosis relapse	16.62	14.26	40	23660	52265	90552482
Condition aggravated	16.48	14.26	90	23610	595455	90009292
Facet joint syndrome	16.29	14.26	3	23697	98386	90506361
Pulmonary oedema	16.12	14.26	44	23656	62036	90542711
Chest pain	15.86	14.26	140	23560	319505	90285242
Joint range of motion decreased	15.57	14.26	8	23692	135635	90469112
Lung disorder	15.55	14.26	10	23690	149873	90454874
Deep vein thrombosis	15.53	14.26	56	23644	91564	90513183
Blood chloride decreased	15.47	14.26	13	23687	6306	90598441
Spinal operation	15.34	14.26	16	23684	10180	90594567
Cervicobrachial syndrome	15.25	14.26	7	23693	1158	90603589
Pupillary reflex impaired	15.11	14.26	9	23691	2536	90602211
Grip strength decreased	14.95	14.26	3	23697	92573	90512174
Hyperreflexia	14.88	14.26	13	23687	6644	90598103
Fear	14.88	14.26	20	23680	16602	90588145
Multiple injuries	14.87	14.26	8	23692	1857	90602890
Pulmonary fibrosis	14.49	14.26	5	23695	107498	90497249

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Respiratory arrest	479.39	18.22	200	10290	28224	42582621
Completed suicide	452.84	18.22	286	10204	96179	42514666
Toxicity to various agents	270.91	18.22	306	10184	228830	42382015
Cardiac arrest	245.88	18.22	208	10282	109112	42501733
Drug abuse	196.69	18.22	180	10310	104591	42506254
Overdose	192.07	18.22	178	10312	105086	42505759
Drug dependence	176.54	18.22	102	10388	28992	42581853
Drug abuser	165.86	18.22	53	10437	3478	42607367
Drug withdrawal syndrome	159.21	18.22	86	10404	21463	42589382
Cardio-respiratory arrest	144.90	18.22	118	10372	58518	42552327
Accidental overdose	107.98	18.22	74	10416	28256	42582589
Poisoning	67.13	18.22	43	10447	14656	42596189
Depression	65.08	18.22	106	10384	111257	42499588
Intentional product misuse	59.95	18.22	75	10415	61825	42549020
Off label use	57.72	18.22	44	10446	638291	41972554
Inadequate analgesia	55.44	18.22	23	10467	3174	42607671
Anxiety	55.09	18.22	102	10388	118458	42492387
Nervousness	48.37	18.22	34	10456	13498	42597347
Road traffic accident	48.29	18.22	39	10451	19054	42591791
Insomnia	42.03	18.22	91	10399	118162	42492683
Drug screen positive	40.62	18.22	20	10470	4111	42606734
Administration related reaction	38.82	18.22	9	10481	172	42610673
Suicidal ideation	33.89	18.22	50	10440	48111	42562734
Neutropenia	32.76	18.22	5	10485	199426	42411419
Exposure via ingestion	32.57	18.22	14	10476	2108	42608737
Hypoaesthesia	32.54	18.22	61	10429	71402	42539443
Back pain	32.24	18.22	92	10398	141684	42469161
Product use in unapproved indication	31.76	18.22	4	10486	184452	42426393
Febrile neutropenia	29.72	18.22	5	10485	185698	42425147
Emotional distress	28.81	18.22	27	10463	16066	42594779
Substance abuse	26.43	18.22	20	10470	8885	42601960
Acute kidney injury	25.34	18.22	32	10458	367305	42243540
Pain	25.21	18.22	123	10367	244725	42366120
Accidental death	24.70	18.22	13	10477	3070	42607775
Drug tolerance	23.91	18.22	13	10477	3277	42607568
Product complaint	23.67	18.22	16	10474	5961	42604884
Respiratory rate decreased	22.41	18.22	12	10478	2933	42607912
Coronary artery disease	22.17	18.22	44	10446	53676	42557169
Amnesia	22.16	18.22	31	10459	28406	42582439
Kussmaul respiration	21.31	18.22	5	10485	101	42610744
Unresponsive to stimuli	21.22	18.22	32	10458	31371	42579474
Back injury	20.54	18.22	13	10477	4335	42606510
Dependence	20.23	18.22	9	10481	1471	42609374
Pyrexia	19.98	18.22	42	10448	394000	42216845
Sinus tachycardia	19.93	18.22	25	10465	20628	42590217
Mental disorder due to a general medical condition	19.72	18.22	5	10485	141	42610704
Ventricular hypertrophy	19.33	18.22	13	10477	4803	42606042
Blood pH decreased	19.30	18.22	10	10480	2288	42608557
Myofascial pain syndrome	19.27	18.22	6	10484	361	42610484
Agitation	18.95	18.22	46	10444	64268	42546577
COVID-19	18.81	18.22	3	10487	115945	42494900
Muscle spasms	18.72	18.22	55	10435	85989	42524856
Intervertebral disc protrusion	18.72	18.22	18	10472	11054	42599791
Injury	18.40	18.22	25	10465	22291	42588554

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	2458.05	13.68	1200	26672	241181	110320246
Respiratory arrest	1257.79	13.68	493	27379	57806	110503621
Toxicity to various agents	820.72	13.68	790	27082	479765	110081662
Cardiac arrest	748.54	13.68	517	27355	196236	110365191
Cardio-respiratory arrest	508.44	13.68	333	27539	115503	110445924
Drug abuse	469.18	13.68	375	27497	177036	110384391
Overdose	409.87	13.68	391	27481	233403	110328024
Drug abuser	280.24	13.68	88	27784	5321	110556106
Drug dependence	231.93	13.68	149	27723	49871	110511556
Poisoning	231.37	13.68	123	27749	28982	110532445
Drug withdrawal syndrome	223.96	13.68	132	27740	37922	110523505
Intentional product misuse	207.71	13.68	209	27663	132695	110428732
Accidental overdose	203.03	13.68	139	27733	51695	110509732
Off label use	156.13	13.68	93	27779	1500092	109061335
Exposure via ingestion	121.68	13.68	46	27826	4854	110556573
Intentional overdose	118.13	13.68	156	27716	132345	110429082
Unresponsive to stimuli	102.66	13.68	102	27770	63688	110497739
Depression	95.47	13.68	232	27640	317103	110244324
Coma	81.62	13.68	123	27749	117746	110443681
Drug screen positive	80.50	13.68	37	27835	6373	110555054
Product use in unapproved indication	74.05	13.68	12	27860	447365	110114062
Accidental death	72.73	13.68	32	27840	4977	110556450
Anxiety	72.40	13.68	221	27651	344857	110216570
Dependence	69.14	13.68	26	27846	2703	110558724
Drug intolerance	67.06	13.68	11	27861	406501	110154926
Neutropenia	59.89	13.68	11	27861	374609	110186818
Synovitis	56.75	13.68	3	27869	274089	110287338
Inadequate analgesia	56.62	13.68	27	27845	5050	110556377
Emotional distress	56.59	13.68	63	27809	44784	110516643
Urinary bladder rupture	55.67	13.68	12	27860	158	110561269
Infusion related reaction	55.22	13.68	14	27858	381148	110180279
Lethargy	51.53	13.68	88	27784	93488	110467939
Coronary artery disease	49.88	13.68	75	27797	71615	110489812
Febrile neutropenia	47.12	13.68	11	27861	316756	110244671
Treatment failure	46.84	13.68	7	27865	277227	110284200
Systemic lupus erythematosus	46.41	13.68	5	27867	254333	110307094
Joint swelling	45.02	13.68	28	27844	442817	110118610
Death	44.01	13.68	314	27558	698555	109862872
Blood pH decreased	43.61	13.68	22	27850	4647	110556780
Nervousness	43.48	13.68	50	27822	36801	110524626
Suicidal ideation	42.37	13.68	81	27791	93856	110467571
Insomnia	40.44	13.68	189	27683	360401	110201026
Acute kidney injury	39.49	13.68	62	27810	635368	109926059
Wound	39.41	13.68	6	27866	234431	110326996
General physical health deterioration	39.09	13.68	30	27842	425265	110136162
C-reactive protein increased	37.99	13.68	5	27867	217914	110343513
Lower respiratory tract infection	37.04	13.68	8	27864	243098	110318329
Suicide attempt	36.98	13.68	81	27791	103313	110458114
Loss of consciousness	36.78	13.68	121	27751	196185	110365242
Substance abuse	36.41	13.68	28	27844	12435	110548992
Somnolence	35.64	13.68	159	27713	297290	110264137
Thrombocytopenia	35.53	13.68	22	27850	348863	110212564
Stomatitis	35.33	13.68	12	27860	270230	110291197
Narcotic bowel syndrome	34.74	13.68	9	27863	270	110561157
Hepatic enzyme increased	34.42	13.68	19	27853	320873	110240554
Back pain	34.21	13.68	184	27688	370812	110190615
Suspected suicide	33.55	13.68	29	27843	15170	110546257
Pyrexia	33.05	13.68	116	27756	898149	109663278
Tarsal tunnel syndrome	32.95	13.68	10	27862	539	110560888
Condition aggravated	32.64	13.68	87	27785	734749	109826678
Helicobacter infection	32.12	13.68	4	27868	181873	110379554
Seizure	31.77	13.68	125	27747	221060	110340367
Intervertebral disc protrusion	31.70	13.68	37	27835	27661	110533766
Sinus tachycardia	31.59	13.68	47	27825	44446	110516981
Intervertebral disc degeneration	31.10	13.68	30	27842	18055	110543372
Feeling abnormal	30.87	13.68	108	27764	180603	110380824
Infection	30.27	13.68	28	27844	362172	110199255
Tremor	29.62	13.68	115	27757	202117	110359310
Drug ineffective	29.42	13.68	244	27628	1520296	109041131
Irritability	29.05	13.68	47	27825	47762	110513665
Discomfort	29.01	13.68	9	27863	214698	110346729
Administration related reaction	28.98	13.68	8	27864	307	110561120
Alopecia	28.40	13.68	30	27842	364723	110196704
Pulmonary congestion	28.40	13.68	37	27835	30929	110530498
Spinal epidural haematoma	28.25	13.68	12	27860	1713	110559714
Myocardial infarction	27.94	13.68	109	27763	191974	110369453
Purpura senile	27.71	13.68	9	27863	606	110560821
Hyperlipidaemia	27.09	13.68	39	27833	35809	110525618
Arteriosclerosis	26.56	13.68	32	27840	24735	110536692
Pancytopenia	26.22	13.68	10	27862	209603	110351824
Soft tissue haemorrhage	26.18	13.68	8	27864	441	110560986
Product use issue	26.15	13.68	24	27848	311671	110249756
Product complaint	25.59	13.68	24	27848	13948	110547479
COVID-19	25.57	13.68	15	27857	245045	110316382
Ventricular hypertrophy	25.47	13.68	18	27854	7027	110554400
Depressed level of consciousness	25.47	13.68	74	27798	112204	110449223
Hypersensitivity	25.47	13.68	39	27833	403959	110157468
Muscle injury	25.10	13.68	3	27869	140804	110420623
Respiratory rate decreased	25	13.68	17	27855	6241	110555186
Interstitial lung disease	24.76	13.68	3	27869	139331	110422096
Leukopenia	24.57	13.68	4	27868	148787	110412640
Peripheral swelling	24.52	13.68	40	27832	403994	110157433
Respiratory depression	24.45	13.68	35	27837	31966	110529461
Mydriasis	24.37	13.68	29	27843	22128	110539299
Mobility decreased	24.12	13.68	15	27857	237407	110324020
Pupillary reflex impaired	23.80	13.68	14	27858	4001	110557426
Psoriatic arthropathy	23.61	13.68	10	27862	196751	110364676
Chest pain	23.56	13.68	169	27703	376206	110185221
Renal impairment	23.55	13.68	9	27863	188436	110372991
Wheezing	23.44	13.68	18	27854	255212	110306215
Nasopharyngitis	23.05	13.68	40	27832	394321	110167106
Abdominal discomfort	22.97	13.68	40	27832	393818	110167609
Therapeutic product effect incomplete	22.93	13.68	14	27858	223791	110337636
Malignant neoplasm progression	22.38	13.68	8	27864	174559	110386868
Hyperhidrosis	22.32	13.68	100	27772	187198	110374229
Ill-defined disorder	22.24	13.68	6	27866	156847	110404580
Rash	22.22	13.68	119	27753	820845	109740582
Intervertebral disc disorder	22.08	13.68	15	27857	5497	110555930
Pain	21.96	13.68	350	27522	954605	109606822
Crying	21.02	13.68	29	27843	25599	110535828
Liver disorder	21.02	13.68	5	27867	142238	110419189
Quadriplegia	20.88	13.68	13	27859	4114	110557313
Drug-induced liver injury	20.34	13.68	3	27869	120064	110441363
Cardiac failure	20.27	13.68	11	27861	187615	110373812
Disease progression	20.22	13.68	19	27853	244015	110317412
Inflammation	19.92	13.68	12	27860	193226	110368201
Resorption bone increased	19.72	13.68	9	27863	1525	110559902
Blister	19.68	13.68	17	27855	227359	110334068
Agitation	19.67	13.68	68	27804	112983	110448444
Hypertensive heart disease	19.59	13.68	13	27859	4583	110556844
Impaired healing	19.20	13.68	13	27859	196704	110364723
Liver injury	19.10	13.68	7	27865	150406	110411021
Mental status changes	19.05	13.68	52	27820	76070	110485357
Asterixis	18.69	13.68	11	27861	3147	110558280
Dysarthria	18.65	13.68	55	27817	84066	110477361
Road traffic accident	18.17	13.68	64	27808	107334	110454093
Myofascial pain syndrome	18.01	13.68	10	27862	2563	110558864
Paranoia	17.88	13.68	25	27847	22349	110539078
Exposure during pregnancy	17.82	13.68	10	27862	167414	110394013
Progressive multiple sclerosis	17.75	13.68	8	27864	1316	110560111
Arteriosclerosis coronary artery	17.07	13.68	26	27846	25092	110536335
Cardiomegaly	16.83	13.68	28	27844	29102	110532325
Spinal osteoarthritis	16.80	13.68	23	27849	20160	110541267
Distributive shock	16.67	13.68	13	27859	5891	110555536
Gastrointestinal disorder	16.58	13.68	22	27850	241930	110319497
Multiple sclerosis relapse	16.44	13.68	38	27834	50202	110511225
Blood alcohol increased	16.35	13.68	7	27865	1019	110560408
Anger	16.33	13.68	22	27850	18985	110542442
Drug tolerance increased	16.27	13.68	6	27866	591	110560836
Neck injury	16.08	13.68	10	27862	3158	110558269
Lip dry	15.85	13.68	3	27869	100080	110461347
Impaired driving ability	15.80	13.68	13	27859	6357	110555070
Accidental poisoning	15.61	13.68	9	27863	2478	110558949
Blood chloride decreased	15.45	13.68	15	27857	9100	110552327
Vestibular disorder	15.13	13.68	9	27863	2623	110558804
Sepsis	15.08	13.68	38	27834	327308	110234119
Epistaxis	15.05	13.68	7	27865	130365	110431062
Tooth loss	15.01	13.68	14	27858	8082	110553345
Multiple injuries	14.87	13.68	10	27862	3604	110557823
Hyponatraemia	14.70	13.68	20	27852	217633	110343794
Generalised anxiety disorder	14.68	13.68	9	27863	2770	110558657
Bronchitis	14.52	13.68	78	27794	156954	110404473
Laryngeal pain	14.41	13.68	12	27860	5963	110555464
Fear	14.36	13.68	23	27849	23170	110538257
Pulmonary fibrosis	14.28	13.68	4	27868	102038	110459389
Withdrawal syndrome	14.07	13.68	27	27845	31353	110530074
Kussmaul respiration	13.90	13.68	5	27867	459	110560968
Miosis	13.88	13.68	22	27850	21961	110539466
Amnesia	13.87	13.68	58	27814	105350	110456077
Anaemia	13.85	13.68	81	27791	547005	110014422
Lung disorder	13.79	13.68	15	27857	180032	110381395
Drowning	13.77	13.68	6	27866	911	110560516

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M03BA02	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
ATC	M03BA52	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
ATC	M03BA72	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:51371	muscle relaxant
CHEBI has role	CHEBI:53784	antispasmodic drug
MeSH PA	D009125	Muscle Relaxants, Central
MeSH PA	D009465	Neuromuscular Agents
FDA PE	N0000175730	Centrally-mediated Muscle Relaxation
FDA EPC	N0000175737	Muscle Relaxant

Related Drugs by ATC class:

M03BA Carbamic acid esters 4 drugs

febarbamate methocarbamol phenprobamate styramate

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Backache	indication	161891005
Spasticity	indication	221360009
Muscle Spasm with Pain	indication
Dependent drug abuse	contraindication	6525002
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Chronic disease of respiratory system	contraindication	17097001
Mood swings	contraindication	18963009
Lowered convulsive threshold	contraindication	19260006
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Alcohol intoxication	contraindication	25702006
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Gastrointestinal ulcer	contraindication	40845000
Hypothyroidism	contraindication	40930008	DOID:1459
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Bradycardia	contraindication	48867003
Vitamin K deficiency	contraindication	52675005	DOID:11249
Nasal polyp	contraindication	52756005
Acute nephropathy	contraindication	58574008
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Sedation	contraindication	72641008
Factor II deficiency	contraindication	73975000
Reye's syndrome	contraindication	74351001	DOID:14525
Gastrointestinal hemorrhage	contraindication	74474003
Urethral stricture	contraindication	76618002
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Decreased respiratory function	contraindication	80954004
Injury of head	contraindication	82271004
Epilepsy	contraindication	84757009	DOID:1826
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hemophilia	contraindication	90935002
Anemia due to enzyme deficiency	contraindication	111577008
Acute abdominal pain	contraindication	116290004
Procedure on urinary system	contraindication	118677009
von Willebrand disorder	contraindication	128105004	DOID:12531
Acute intermittent porphyria	contraindication	234422006	DOID:3890
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Lesion of brain	contraindication	301766008
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Primary adrenocortical insufficiency	contraindication	373662000
Operation on gastrointestinal tract	contraindication	386621005
Pseudomembranous enterocolitis	contraindication	397683000
Breastfeeding (mother)	contraindication	413712001
Central nervous system depression	contraindication	418072004
Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	422681000
Poor metabolizer due to cytochrome p450 CYP2C19 variant	contraindication	424500005
Dysfunction of sphincter of Oddi	contraindication	430887001
Acute erosive gastritis	contraindication	444926003
Acute exacerbation of asthma	contraindication	708038006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018454	VUID
N0000146778	NUI
D00768	KEGG_DRUG
2101	RXNORM
C0007248	UMLSCUI
CHEBI:3419	CHEBI
CHEMBL1233	ChEMBL_ID
DB00395	DRUGBANK_ID
D002328	MESH_DESCRIPTOR_UI
2576	PUBCHEM_CID
7610	IUPHAR_LIGAND_ID
902	INN_ID
21925K482H	UNII
4359	MMSL
747	MMSL
d00960	MMSL
25076002	SNOMEDCT_US
387133006	SNOMEDCT_US
4018454	VANDF
001672	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Soma	HUMAN PRESCRIPTION DRUG LABEL	1	0037-2001	TABLET	350 mg	ORAL	NDA	31 sections
Soma	HUMAN PRESCRIPTION DRUG LABEL	1	0037-2250	TABLET	250 mg	ORAL	NDA	31 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-033	TABLET	350 mg	ORAL	ANDA	28 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	10544-088	TABLET	350 mg	ORAL	ANDA	29 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-132	TABLET	350 mg	ORAL	ANDA	27 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	12634-437	TABLET	350 mg	ORAL	ANDA	32 sections
carisoprodol	Human Prescription Drug Label	1	16571-780	TABLET	250 mg	ORAL	ANDA	29 sections
carisoprodol	Human Prescription Drug Label	1	16571-781	TABLET	350 mg	ORAL	ANDA	29 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-039	TABLET	350 mg	ORAL	ANDA	27 sections
SOMA	HUMAN PRESCRIPTION DRUG LABEL	1	16590-755	TABLET	250 mg	ORAL	NDA	29 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL WITH HIGHLIGHTS	1	21695-021	TABLET	350 mg	ORAL	ANDA	29 sections
Carisoprodol and Aspirin	HUMAN PRESCRIPTION DRUG LABEL	2	21695-570	TABLET	200 mg	ORAL	ANDA	19 sections
Soma	HUMAN PRESCRIPTION DRUG LABEL	1	21695-606	TABLET	250 mg	ORAL	NDA	29 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	29033-207	TABLET	250 mg	ORAL	ANDA	30 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	29033-214	TABLET	350 mg	ORAL	ANDA	30 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	33261-387	TABLET	350 mg	ORAL	ANDA	28 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	33358-064	TABLET	350 mg	ORAL	ANDA	29 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	42543-700	TABLET	350 mg	ORAL	ANDA	30 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	42549-503	TABLET	350 mg	ORAL	ANDA	27 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	43353-102	TABLET	350 mg	ORAL	ANDA	31 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	45865-233	TABLET	350 mg	ORAL	ANDA	26 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	45865-984	TABLET	350 mg	ORAL	ANDA	30 sections
Carisoprodol	Human Prescription Drug Label	1	50090-0280	TABLET	350 mg	ORAL	ANDA	30 sections
Carisoprodol	Human Prescription Drug Label	1	50090-0281	TABLET	350 mg	ORAL	ANDA	30 sections
CARISOPRODOL	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3048	TABLET	350 mg	ORAL	ANDA	32 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3232	TABLET	350 mg	ORAL	ANDA	33 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4261	TABLET	350 mg	ORAL	ANDA	27 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4263	TABLET	350 mg	ORAL	ANDA	27 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4744	TABLET	350 mg	ORAL	ANDA	31 sections
Carisoprodol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4746	TABLET	350 mg	ORAL	ANDA	31 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

carisoprodol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: